Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)

NCT01868997 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01868997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01868997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
February 22, 2017
Enrollment
88 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid associated ophthalmopathies, thyroid-associated ophthalmopathy